Depression Education Impact on Chronic Heart Failure Patients
This study aims to evaluate if providing depression education materials can enhance your understanding of depression's impact on individuals with Congestive Heart Failure, as measured through a questionnaire.
Receiving educational material of depression care
+ Receiving educational material of depression care
Behavior+3
+ Behavioral Symptoms
+ Cardiovascular Diseases
Summary
Study start date: May 1, 2004
Actual date on which the first participant was enrolled.This study focuses on understanding the impact of depression on individuals with Chronic Heart Failure (CHF). It's known that depression can worsen the outlook and limit daily activities for people with CHF. However, depression often goes unnoticed in these patients. The study aims to evaluate how depression affects the prognosis of stable CHF patients receiving outpatient care. Additionally, it explores whether providing depression education to CHF patients can enhance their depression care. In this study, patients with chronic heart failure are enrolled and half of them are randomly selected to receive a packet of depression education materials, while the other half do not. Both participants and researchers are unaware of who receives the materials. All participants can contact the research team using a toll-free number whenever needed. Depressive symptoms and patients' understanding of depression are evaluated at the start, then 1-month and 6-months after enrollment. The study examines changes in depressive symptoms and requests for psychiatric help between the two groups.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.270 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: Inclusion Criteria LVEF ≤ 35%. NYHA class II, III, or IV heart failure for the previous three months despite a minimum of 6 weeks of treatment. Must be on optimal heart failure therapy according to AHA/ACC and HFSA heart failure guidelines, including treatment with ACEI and beta-blocker therapy, or have documented rationale for variation, including intolerance, contraindication, patient preference, or personal physician's judgment. Exclusion Criteria: Age less than 18. Currently pregnant or intending to become pregnant in the next year. Cardiovascular procedure or hospitalization for any reason planned in the next 6 months. Expectation of receiving a cardiac transplant in the next six months. Unable to provide the study consent. Participation another clinical trial(s) that may interfere with follow-up or data collection for this study, or that may affect cardiovascular mortality.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
ShamStudy Objectives
Primary Objectives
Secondary Objectives